Miller-Fisher syndrome (MFS) is classified as a variant of Guillain-Barr e syndrome (GBS), accounting for 5%-25% of all GBS cases. Since the coronavirus disease-2019 (COVID-19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS-CoV-2 infection test.

Highlights A clinical worsening in CIDP may occur in concomitance with COVID-19. Cytokine hyperactivation triggered by SARS-CoV-2 infection might be a possible mechanism. The management of these patients is particularly challenging.

No abstract

No abstract